Innovafeed and Ambiotis have published research demonstrating anti-inflammatory properties of Hilucia for Pets, an insect-based ingredient derived from black soldier fly larvae, ahead of Interzoo 2026.
The in vitro study, conducted by Ambiotis, a contract research organization specializing in inflammation resolution, measured cytokine secretion in canine whole blood incubated with the hydrosoluble fraction of Hilucia for Pets, 18 hours after immune stimulation with LPS, a pyrogenic bacterial endotoxin.
Researchers quantified three cytokines: TNF-α, a pro-inflammatory cytokine; IL-10, an anti-inflammatory cytokine; and IL-6, which has both pro- and anti-inflammatory effects.
Dual modulation of cytokines
Key findings include a reduction of TNF-α to levels comparable to dexamethasone, a reference anti-inflammatory compound, at a concentration of 1 gram of Hilucia for Pets hydrosoluble fraction per liter of blood. IL-10 production increased with exposure to the hydrosoluble fraction, even at the lowest tested concentrations. IL-6 secretion was inhibited at lower concentrations but increased above the negative control at concentrations of 16 grams per liter or higher.
The companies noted the ingredient's cytokine modulation differs from conventional anti-inflammatory compounds such as dexamethasone, which tend to suppress all cytokine secretion. The hydrosoluble fraction selectively reduced or increased cytokine secretion depending on each cytokine's role in inflammation resolution.
"The resolution of inflammation is a key physiological process that restores tissue balance while maintaining immune system effectiveness," said Gérald Chêne, head of laboratory at Ambiotis. "Through its dual modulation of cytokines — stimulating IL-10 and inhibiting TNF-α — Hilucia provides an innovative mechanism of action that naturally activates the body's own pathways for resolving inflammation."
Insect protein as a functional ingredient
Researchers attributed the observed effects most likely to the presence of polyphenols and short-chain peptides in the hydrosoluble fraction. The companies hypothesize that a 3% inclusion rate of Hilucia for Pets in dog kibble would deliver sufficient compounds into the bloodstream to affect inflammatory state, based on assumed bioavailability and average canine blood volume. The companies note that further in vivo testing would be needed to confirm the inclusion rate required to achieve active blood concentrations.
"This study marks an important milestone in demonstrating that insect-based ingredients can play a functional role in pet health," said Amélie Maurice, R&D engineer at Innovafeed. "With our Hilucia for Pets range, we are introducing a new generation of solutions that combine performance, science and sustainability."
Chronic inflammation in dogs and cats is associated with skin disorders, digestive issues, joint disease and reduced overall well-being, noted Innovafeed. The research suggests potential applications of Hilucia for Pets in sensitive diets, skin and coat health, digestive health, joint support and mobility, and weight management formulations, it said.
The white paper noted that results and potential benefits should be regarded as sources of inspiration for end-products and must comply with applicable local regulatory requirements.
The full white paper is available at innovafeed.com. Innovafeed will present Hilucia for Pets at Interzoo 2026, Hall 1, Booth 522.
